Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

X4 Pharmaceuticals (XFOR) Revenue (2018 - 2025)

X4 Pharmaceuticals' Revenue history spans 6 years, with the latest figure at $2.6 million for Q4 2025.

  • For Q4 2025, Revenue rose 79.08% year-over-year to $2.6 million; the TTM value through Dec 2025 reached $35.1 million, up 1273.21%, while the annual FY2025 figure was $35.1 million, 1273.21% up from the prior year.
  • Revenue reached $2.6 million in Q4 2025 per XFOR's latest filing, up from $1.8 million in the prior quarter.
  • In the past five years, Revenue ranged from a high of $28.8 million in Q1 2025 to a low of -$1.1 million in Q4 2022.
  • Average Revenue over 4 years is $2.7 million, with a median of $561500.0 recorded in 2024.
  • Peak YoY movement for Revenue: fell 21.47% in 2023, then surged 250.44% in 2025.
  • A 4-year view of Revenue shows it stood at -$1.1 million in 2022, then grew by 3.06% to -$1.1 million in 2023, then surged by 229.31% to $1.4 million in 2024, then soared by 79.08% to $2.6 million in 2025.
  • Per Business Quant, the three most recent readings for XFOR's Revenue are $2.6 million (Q4 2025), $1.8 million (Q3 2025), and $2.0 million (Q2 2025).